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Oral cephalosporins in uncomplicated urinary tract infections
IJcp.lfllllem 0 Mlt:rohlo]ol,')', I ml'ual UIlIVCrslt.1r10 De S,blllallca Sabll1:lIlL, Spalll
UllllJry tr,ld 1IllCCtlOllS (UTls). ddilled as the presnlce of
Iltl roorganl'I11.S In thc unm', ;In: the s<"("olld Illost frequenr
COllllllullity-a qUlred lllfcct!ons after r<'spir.HolY tr.l·t Init:,,-
nom. In f:ell<'ral. UTIs Jre Illor,' fretjuent \11 wOlllen, though
rim heh,l\'lllt IS dltlcrent in ,Ollie ,Ige groups. In inl;lI1ts up to (,
months Th ar<' Illuch more Ir,'qul'llt III male: alter (, nWl1lh,
UTls b,'collle lllore fi·,'quent In fem:t1cs. The prevaknc,' of
UTI> In WOlJ1,·n. frol11 the preschool ycars to adulthood,
range frolll 1.5% to 4.5%. Ulllubtlv,' IIlCldence llfsYlIlpto-
l11aric UTI .luring the tir.t In years ofliie: \Va :\% 111 gJrl Jnd
I. loy" 111 bllyx 111 1974 III, hut r<'C('11t sllIdi("s led to hlgh,'r
Igun" 111 boys (1.(,%), al1d <"specially 111 girls (7.H'Vr,) [21·
UTI prc:valcnce In adult WOl11ell who .11... not I'regn.ll1t b
ahollt 1'\{r-3'~", whereas preval('ne<' III males relllains around
n.1 'Y.. 131. In the elderly tim r.mn ch. nges dramatically. and the
t<'m,lldnl,lle ratio Jecrc.1se, fi-OlJ1 JOI J III YOllllf: adults to 2/1
Morco",'r, rill' prevJlc:nCl' rlSCS suhstantlally ill both sexes 111
the ,'Iderly (, round 10% in 1l1<:n Jnd 20% III wOlllen).
)VCl.IU. wrvey SUggl'St th.ll ar utld 7 11111110n <:.1. ,'s of,l ute
cystitis and at lea,st 2511 OliO p~'e1onephntis ,Ire diaglloscd e\'el)'
year 1lI thc U 'A. NeverthcIL-ss. reCcllI st11dies show thaI the
IlIndcnc,' ( I' <"y,ml~ would Lll' roulld 0.5-0.7 cases/persolll
year, 01111' III .Ollllg, \CXll,llly actlVC womctl. Tl\L'll. the rcal
IIICldclICC 1l1lght be .Igndicantly higher. slIlce th(.'s(.' !il-o"lll'e~
wOllld IIIcall ,111 illcldcllce of .It kast 25-J5 nllllion ca~cs/year
III the USA Pl.
The al1nblotic trealll1cnt of UTls is mJinly rationalized by
three Clrcllll1Stallces:
They arc usually mild Ill/i:niom th,lt do IlOt re'\llIte
hospltahzalloll. Th,,' .IIlllblOtlC> with ,'a~y ad1l111llstratlOll,
111.1 lilly oral .1IltlblOncs. ,1fC pr<'lclTed,
.2 -lItl'r b, ct,'rla. m:11l1ly E,'"lIerir!lill wli, arc hy ':'1' thc 1110,1
in.' IUCIlUY 1Il1i: ung (lrg-am 1m III COlllmUllir -acqulrcd.
ulll'olllph ';Ite,l UTI\. hIlS, antibiotics, ctlve ah':,unst thl's,'
min org:llllsll15 should be med.
,\ The anubl tic .houId rcach . dequ,ltc cOl1cemratioll III lin 11<'.
t'orrL"polldllll,: .uthor alld repllllt r«,"<"~: I'rof J A ;, r(la-
Rodngllcz. Ikp.mllelll of u;rohlOl0!O'. Hosplt.1 Ulllver<il.ltlO de
'i.llalll.tlll:•• I'a'eo de San V"'L'IJ[e Illx . .I7tHl7 S.lblll.IICJ. Sr Jill
T d . + .4 1)23 2(,4825
r-J": + ,\4 '123 26226 \
E-II1;ul JoIg.1rrod@b'U!:\J.us.:ll.es
This way, the drug ofchOicc {or unc01nphc:lrcd, COInmlllUty-
acqUired U h would be all oral antibIOtic with phanll:lcoki-
Il('nc, allowlllg II1tTeqU('l1t dosmg Intervili and ad...quate
urinary levell, active agamsl E. r(1/' alld the other barrena
1ll0St fr"lJlIcmly in\' Iwd, wuh a low inCIdence of sidc-dfe
.md ala\\' ltlClJencc of acquired re ht~n e am Ilg the mosl
frequt'1l1 pJrhogens.
A numbcr of antibIotics havc been used tor tile rreamlcnt 01
UTls: pem dims, I cl1Iclllinl ~-laetal11:l.se mhibitor C mbmJ-
naIlS. <:cl'halosl'nnm. alllinogl)-'co,idc~, SIIUOnJllIIdc..s, non-
fluorinated Jnd OllUtlll.1tl'd qllinolofK'S, etc
Among all thcse dnJ~, the usc of ora,) C"l'phalmrorins 15
riSlI1g as :t re,ull of sl'vc•.J [actors, related both to tht'
mlcroorgal1lSII1$ IIlvolved Jnd to the dru~rs.
Parenteral <:ephalosponns ami oral cephaJosponltS haw
evol""o 111 a diOcrel1t W:I)'. Par"nteral ephalosponns have
evolved III' ttl four gcneranOIL~.wIth. I'rogre slve ll\ rease m
their .lCtivity af:,'3U'bC nUlllerous mIcro rg;lmsllt'i. e pc 1.1.11'1
;ralll-lIcgatlVes. MeanwluIe, for a nUll1ber of yerlrs, oral
cephalosronns have been a relatively snull group of
compounds bclollgin~ to the lim- or second-generatlol1
cephalmpotlns. WIth a Imllled al1olll1crohla.! spc trum 141,
The changc 111 the etiology oi ~c"erc h pical-a qlllrcd
infections.. nd m the SlI 'ptibillty prolilc of baclena causing
rhel1l, w(.'re ,Il'cisive f.tCIOl'\ for the:- developmcnt of 1" remer:ll
cphalosporin" The dl'vclopment f oral ephalosporins OVt'r
the past years was much slower, bee. u~e for years the
ctlologlcal Jgen CJllSIllf: conunumtY-3 quued mfe:cnons
changed only h~hcly, anJ 1110 I of the e palh gem wert'
susceptible to the tir:<l ral cephalo ponn I~I
H.esi,tanc(' to cOlllmonly u cd anoblllli s IS he ollllng
fi'equem amol1l? :t number of microor\;'dlll IlU lf1\'olved In
COlll1l1l1lltty-acquired mIt: nom, mduding bJcwna call\lIlg
COlllmumty-acqUlred UTI<, and mamly E (1/i, Resl t;II1Ce." to
sllifonanlldc dnd tnlllethopnm/sulfunl<.'thoxnol (TIS) IS now
ncar 5U%, .IllU eSISlance to au roqullloiones IS lI1credslllg In E
(.,Ii. rca hmg f1gllrC's hIgher thall 25% 111 pam. H. ... I rance to
penicillin omed hy older plasl1l1d-nwJIJte."d ~-lal'IJIll:lSe, IS
ll'cquent, :lnd re>lSlan l' co Pl"1lI i1hn/!3-1.ll"tam3\e mhlbllor
eOlllbmatlons me hated b the ne\Ve."t pia 1I11d-l1le."dl~ted IRT
cnZYlllCS IS found III 15% of E. rol,l alate.". by ome authors 15).
The cIt: nges III the e nrculustJnces dunng the I tears
have been JenSI e factO In the de"e1opment of or:u
, 2000 Copyl'lgh\ by lhe Elltopean Society of Clinical Microbiology and Infecuous Diseases. eMI. G (Suppl 3). 73-75
Table 1 Susceptibility 10 antibiotIcs 10S1od In 504 isolatos from
pallonls with uncomplicated UTis
UTls [7] (Tablcs I and 2). vcr a 3-month pf;riod we tudied
1000 outp3tJcnts. 533 of whom were eJected r. r the rudy
according 10 criteria previously established. orne 507 patients
(95.1%) Ita UTls caused by ram-negative bacteria. he
III St frequent agclll wa. E. (eli (84%). followed by Klt'bsit'lla
ImwlIllllltat: and [>rlltCIIS lIlirabilis (4.9% each). In vitro activity of
coamoxidav, trimellloprimhulf.1.methoxazolc (TIS), pipe-
midi acid. 1l0rfloXl cin, cefuroximc axetiJ and ccfixilllc was
studied a ?:ullsr thes~ microorganisms.
Both coarnoxiclav and TIS were activc again.~t less than
70% of StraHl!, nd plpCllUdic acid against less than 80%.
ephaI ponlls wcre the anribi tics dut had the be t pr £ilc-,
cC'fLxime being. nve 3g;tinlt 99,2% of scrains. These results
conJinn previ us dlt:1 from a study pl.'Cfonl1l~d in 1992 In rhe
UK on clinical urinary isolatcs, in wluch resisr:mce to cefiximc
\;) lower than resistance to most other :ull:ibiorics used ill the
trcatment of community-acquired. uncomplicated UTls,
excepting s me f1uoroquinolollc [8.91,
Studies 011 the treatJnenr ofconllnunity-acqu:ired UTls with
cefix.imc show that results arc similar ar lea.~t to other j}-la r31llS
and fluoroquinolones. A double-blind soldy comparing -day
regimens of celixime (400 mg once cLliIy) and o1loxacin (200
mg twice a day) for the crcatJnenr of uncomplicared UTls JIl
women showed dinicaJ cure rate afrer 1 \ eek and after 4
weeks of 89%/81% for efiximc and 92%/84% for ofloxacin
rIOJ. Mierobiologlcal eradication rates were 83%/77% for
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cepluJosporim. Thm, Wt: now h.we . vailable oral cephal -
ponm belongmg to the first, second and third gcncr.lIion,
whose spectrum include the most frequent urinary tract
pathogens and with pharnl!lcokil1crics aJJowmg infrequent
Josmg II1tcrv, L and good unnary It:vcls.
Mmt third-gclwrari 11 raj eph. J porin.. in common
with ec n I-gencratlon oral ccphalo prins. . re proorugs.
c~ten.ficd at po'ition 4. This feaom: pennit~ their r:tl
adnumstrarlOn and absorption. being hydrolyzed in the
igcstlve tract by 110n.~pecific estera.~es 1~1.
Among the molecules that rc d.ire.cdy absorbed widlOut rhe
need ofcstenfic. riOI1 i cefixime, the Ii t orallhird-gellerarion
cphalosponn to be marketed. It is an aminothia7.0le-
methoxyinuno-cephalosporin. whICh becau e of i~ vinyl
group 111 pOSItlOll 3 can be direct!, absorbed 1'41.
As tor most third-generation oraJ cephalosporins. cefucime IS
acrive ag:unst microorgJlllsms causing COllllllllluty-a quircd
UTls. nd is only hyJroly-.red by c.xtended spectrum ~-IaC"lIJ1;LSes
and high levels of chromosomaUy mediated cephaJo. porillJ' s.
From a phaI1l1:I(;okinetic point of view, cefix.ime shows
values Igni6canlly higher than other oral ceph:\losporins for the
maIO parameter.;. Most th.ird-generation oral cephalo ponns
reach C",n 1.5-3 h after adnunistratiol and bave a h:llf-life of
approxunatcly 2- h. For cc6xime, 7;". is a lJrtle longer (3.7-4
h). bur half-life is also longer (3.5-3.8 h). em,x (or efiximc i.~
3.5-4 mg/L after a mgle 400 rng dose:, ~ching .8-5 Ing/L
mer multiple 400 Illg doses. The levels of wina()' ex retion
range from 20"AllO 40";" [4). Tlus pharmacokinetic profile allows
once-a-day administration. Tb.is is a very importaJJt fa t in
IllfcCtlon treat~-d in the conmIII niry. where ol1ce-a-day
admmistratlons lead to ;) very higil proportion of compliance.
bile compliance de rea~es for twice-a-day administrations,
and marketUy when 3dministration i every or 6 h [6].
The ill "itro ctiviry of cefixime is similar to other third-
genera.cion cephalosporins, aod it is clearly more active than
second-generation an Jogs.
We have rec 'nlly conducted microbiologi study on the















Table 2 In vi/fo activity of ceflxime and four olhe, cephalosporins agamst urinary tract pathogens
M1Cuo (~gfmL)
Cefixime Cefuroxlme Cefetamet Cefpodoxime Ceftlbuten
E. coli 0.5 4 1 0.5 0.2
K. pneumonia8 0.2 8 0.5 0.5 0.1
E. ctoacBB >64 >64 >64 64 >64
C. (roundii 8 >64 2 8 4
P m rabitls 0.06 4 0.1 0.1 0.03
M. morganii 64 >64 64 64 32
P. aBrugino$IJ >64 >64 >64 >64 >64
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cdixl111l' .111<1 l'Wy',/XO% li,r ollllxJCill. J)ifti'rcllrt:~ Wl're lIot
'lb'lliIlOl1l III • Ily l.I\t', \0 Ih<' dlic.Ky 01" both rt"gtlll<'ns r.1l1 be
cnmidercd 511111br fi)r tht" Ir,·;,tllll·1I[ 01" UTls III wonl<:lI.
A1l0l her ,{lIdy reponed 111 J.I\'.1I1 III 1'>92 ,howed th;,t cdixlIllC
Iud all OVC1';'!1I efl~cnvcm'~\ rJrl' III the m:.ltIllClll of ;'!clIte
1Illcollll'hc:llcd y,ml" wh<'n gJv<'n b.l.d., of 9-1%. Jnd 'Jm{,
when !{I"<'II (1nce .1 ,l.Iy. With only 011<' 0'<' \11" sl,k-clfcCl
(\lOlIUtlU\) ,1I110nl-: lhc 71 W0111CII IIlclllJcd in thc study 1111.
StlIdlc. involvllll-: '1lIldrcl1 ,how th.lt cl'lixi111 l' IS .tI\u Jil
cxcdlcnt ;,ltl'rnJrn'c for thl' trc;,tllIcnt or' UTI, III rhl, g"roup. A
study pcrfonlled 111 G<'nnany In 25 c1l1ldren and youllf( ;'!dllits
wtlh mydolll,'nlnl-:0 'dc showcd a lU,U!" effiL;'cy, \ Ith \Ide-
clrcetl (1)0111lt111g) In only ol1e pa{lelll 1121. A rccent
cl1IllI'JratlVl' ~tUdy bClwl'cn ctixlltlc and T / 111 childrl'l1
.111.1 a 11I1t, ,ho\\,ed lh.ll cclixlll1C W:15 active ag:linst IDO'v., of
Isobtes, whdc T /. was actlVc only ag-all1>t 85%. No t:,ilurl's
were observl'd, and relapse ocel!red \ll two cases with cdixlme
:1I1d In onl' en: wllh T/ [121. Fil13l1y, a srudy on oral
trl'atlllt:m of UTls m children With coall1oxicbv and CCfiXlIIll'
,howl'd tlt;'!t curc r.1tl'S weI'" X4'Y<, With cdixilllc ;,!l1d l:l2'X, With
cO:lll1oxicla\' 113I.
"crall, dL'l:IIllC 15 a third-gcl1cr.1tlon 0r.11 eephalO'.poril1
that, III ullcomplicated UTI, IS active ;'!gain.t almost all
ctlologlcal ;'!gcllts. IS at Ieasl as df.:eti vc as ocher usual
rrea till C IltS , I as cfficaclOu when gIVen once as when given
tWice, day, and h:\s a vcry low rate of Idc-dIeets. Morcovcr,
the uall OSI of a trcatment wieh cetixlI1ll: -10 J IIlgl2-1 h in
Spain, is 60 PlS (son1l' 2.9 euros) , sU11Jhr to antibioti s with
.nnllar effica y such as ciprol1ox. cin ;'!nd 'Cfllroxilllc ;'!xctil,
and cheapen than other oral third-gener.1C1on cephalosporin.s
such as ecftlbutcn (7-10 ptS, around 4.3 curos). Thus tlllS oral
cephalosporin IS an cxcdlcm alr':rI1atlvc for the tre, tlllCIH or
l'Clllllllunlty-aequJrc , uncolllplicatcd UTls.
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